Pyxis Oncology Inc (PYXS)

Apr 05, 2026

Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell - marketbeat.com

Apr 05, 2026

Apr 04, 2026

PYXS Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 04, 2026

PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 04, 2026

Mar 31, 2026

PYXS Earnings History & Surprises | EPS & Revenue Results | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill

Mar 31, 2026

Mar 30, 2026

Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Mar 30, 2026

Mar 29, 2026

Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst - The Globe and Mail

Mar 29, 2026

Mar 28, 2026

Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - marketbeat.com

Mar 28, 2026

Mar 27, 2026

PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill

Mar 27, 2026

Mar 26, 2026

Stock Report: Can Pyxis Oncology Inc expand its profit marginsDividend Hike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn

Mar 26, 2026

Mar 26, 2026

Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - marketbeat.com

Mar 26, 2026

Mar 26, 2026

Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com Australia

Mar 26, 2026

Mar 25, 2026

Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan

Mar 25, 2026

Mar 25, 2026

Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com UK

Mar 25, 2026

Mar 25, 2026

Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - stocktitan.net

Mar 25, 2026

Mar 25, 2026

Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - stocktitan.net

Mar 25, 2026

Mar 25, 2026

Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan

Mar 25, 2026

Mar 25, 2026

[Form 4] Pyxis Oncology, Inc. Insider Trading Activity - Stock Titan

Mar 25, 2026

Mar 25, 2026

Director at Pyxis Oncology (PYXS) receives grant of 45,867 stock options - Stock Titan

Mar 25, 2026

Mar 25, 2026

Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares - MarketBeat

Mar 25, 2026

Mar 25, 2026

Pyxis Oncology (PYXS) director sells 15,496 shares under 10b5-1 plan - Stock Titan

Mar 25, 2026

Mar 25, 2026

FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst - MarketBeat

Mar 25, 2026

Mar 24, 2026

LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Mar 24, 2026

Mar 24, 2026

A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo

Mar 24, 2026

Mar 24, 2026

Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00 - marketbeat.com

Mar 24, 2026

Mar 24, 2026

Stifel cuts Pyxis Oncology stock price target on financing assumptions By Investing.com - Investing.com India

Mar 24, 2026

Mar 24, 2026

Pyxis Oncology (NASDAQ:PYXS) Given Buy Rating at HC Wainwright - MarketBeat

Mar 24, 2026

Mar 24, 2026

Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data By Investing.com - Investing.com South Africa

Mar 24, 2026

Mar 24, 2026

Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com India

Mar 24, 2026

Mar 24, 2026

H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target By Investing.com - Investing.com Australia

Mar 24, 2026

Mar 24, 2026

H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target - Investing.com

Mar 24, 2026

Mar 24, 2026

Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus

Mar 24, 2026

Mar 24, 2026

RBC Capital Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $5 - Moomoo

Mar 24, 2026

Mar 24, 2026

Stifel cuts Pyxis Oncology stock price target on financing assumptions - Investing.com

Mar 24, 2026

Mar 24, 2026

Pyxis Oncology Reports 2025 Financial Results, Advances MICVO Cancer Trials, and Announces New Leadership - Minichart

Mar 24, 2026

Mar 23, 2026

Pyxis Oncology Reports Q4 Results, Advances MICVO Program - TipRanks

Mar 23, 2026

Mar 23, 2026

William Blair reiterates Pyxis Oncology stock rating on trial pace By Investing.com - ca.investing.com

Mar 23, 2026

Mar 23, 2026

William Blair reiterates Pyxis Oncology stock rating on trial pace - Investing.com UK

Mar 23, 2026

Mar 23, 2026

Jefferies raises Pyxis Oncology stock price target on drug data By Investing.com - Investing.com Australia

Mar 23, 2026

Mar 23, 2026

Jefferies raises Pyxis Oncology stock price target on drug data - Investing.com

Mar 23, 2026

Mar 23, 2026

MicuRx Pharmaceuticals: Advancing Novel ADC Therapy MICVO for Difficult-to-Treat Head and Neck Cancer – Pipeline, Strategy, and Risks Overview - Minichart

Mar 23, 2026

Mar 23, 2026

Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 23, 2026

Mar 23, 2026

Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat

Mar 23, 2026

Mar 23, 2026

Pyxis Oncology 10-K: Revenue $13.9M; Net loss $(79.6)M - TradingView

Mar 23, 2026

Mar 23, 2026

Pyxis Oncology (PYXS) highlights MICVO ADC progress in head and neck cancer - Stock Titan

Mar 23, 2026

Mar 23, 2026

Pyxis Oncology : March 2026 Corporate Deck (ae13e6) - MarketScreener

Mar 23, 2026

Mar 23, 2026

Pyxis Oncology (NASDAQ: PYXS) details 2025 results and MICVO head & neck cancer data - Stock Titan

Mar 23, 2026

Mar 23, 2026

Pyxis Oncology 2025 net loss widens on higher R&D spend - TradingView

Mar 23, 2026

Mar 23, 2026

BRIEF-Pyxis Oncology FY Net Income USD -79.621 Million - TradingView

Mar 23, 2026

Mar 23, 2026

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire

Mar 23, 2026